Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Allison Berger"'
Autor:
Maria Patra-Kneuer, Stefan Steidl, Akito Nakamura, Andrea Polzer, Stephen Grossman, Igor Proscurshim, Carmen Ginzel, Keli Song, Christina Heitmüller, Allison Berger
Publikováno v:
Blood. 138:2268-2268
Introduction TAK-981 is a first-in-class small molecule inhibitor of the SUMO activating enzyme currently in Phase I/II clinical trials. TAK-981 has been shown to increase NK cell activation and M1 macrophage polarization via upregulation of Type I i
Autor:
Alejandro Gomez-Pinillos, Alonzo Martinez, Allison Berger, Amitkumar Mehta, Deborah Berg, Stephane Doucet, Paolo Caimi, Tycel Phillips, Lapo Alinari, Brenda W. Cooper, Bo Chao, Christine K. Ward, Igor Proscurshim, John Gibbs, Sarit Assouline, Alexey V. Danilov, Sharon Friedlander, Steven I. Park
Publikováno v:
Blood. 138:2488-2488
Background: TAK-981 is the first small-molecule inhibitor of SUMOylation to enter clinical trials. SUMOylation is a post-translational modification in which small ubiquitin-like modifier (SUMO) proteins are activated and covalently attached to substr
Autor:
Erlene K. Seymour, Allison Berger, Dennis Huszar, Dejan Juric, Afshin Dowlati, Igor Proscurshim, Anthony J. Olszanski, Alejandro Gomez-Pinillos, Jordi Rodon Ahnert, Bingxia Wang, Arkadiusz Z. Dudek, Sharon Friedlander
Publikováno v:
Journal of Clinical Oncology. 39:TPS2667-TPS2667
TPS2667 Background: SUMOylation, a posttranslational modification analogous to ubiquitination, attaches a small, ubiquitin-like modifier (SUMO) to target proteins. SUMOylation plays a central role in regulating type I interferon (IFN-I)-dependent inn
Publikováno v:
Leukemialymphoma. 60(12)
With the advent of proteasome inhibitors (bortezomib) and pleiotropic pathway modulators which target cereblon E3 ligase (lenalidomide), the ubiquitin-proteasome system has emerged as a tractable target in non-Hodgkin lymphoma and multiple myeloma. H
Autor:
Craig Okada, Alexey V. Danilov, Nur Bruss, Allison Berger, Cody Paiva, Tingting Liu, Adam Kittai, Scott R Best, Taylor Hashiguchi
Publikováno v:
Blood advances. 3(1)
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin lymphoma (NHL), no
Autor:
Steve Stroud, Jade Lyons Rimmer, Emanuela Ercolano, David A Hilton, Claire L. Adams, Allison Berger, C. Oliver Hanemann, Mahindra Makhija, Daniele Baiz, Sells Todd B
Publikováno v:
Cancers
Volume 12
Issue 7
Cancers, Vol 12, Iss 1744, p 1744 (2020)
Volume 12
Issue 7
Cancers, Vol 12, Iss 1744, p 1744 (2020)
Meningioma is the most common primary intracranial tumour, and surgical resection is the main therapeutic option. Merlin is a tumour suppressor protein that is frequently mutated in meningioma. The activity of the E3 ubiquitin ligase complex, CRL4-DC
Autor:
Alexey V. Danilov, Taylor Hashiguchi Rowland, Allison Berger, Adam Kittai, Scott R Best, Vi Lam, Nur Bruss, Tingting Liu
Publikováno v:
Blood. 134:4313-4313
Introduction: Inhibitors of B-cell receptor associated kinases (e.g., Bruton tyrosine kinase and phoshpoinotiside-3 kinase) have led to significant improvement in outcomes of patients with CLL. Furthermore, such therapies have immunomodulatory effect
Autor:
Dennis Huszar, Allison Berger, Alejandro Gomez-Pinillos, Mi-Sook Kim, Amitkumar Mehta, Igor Proscurshim, Chirag Patel, Paolo Caimi, Bingxia Wang, Sarit Assouline, Sharon Friedlander
Publikováno v:
Blood. 134:1593-1593
Background TAK-981 is a first-in-class, small molecule inhibitor of SUMOylation, a reversible post-translational modification that regulates protein function by covalent attachment of small ubiquitin-like modifier (SUMO) proteins to a protein substra
Autor:
Alexey V. Danilov, Jennifer R. Brown, J. Claire Godbersen, Cody Paiva, Olga V. Danilova, Allison Berger
Publikováno v:
Leukemia & Lymphoma. 56:1566-1569
Chronic lymphocytic leukemia (CLL) B-cells demonstrate both constitutive and stroma-mediated activation of nuclear factor-κB (NF-κB). NEDD8, a ubiquitin-like protein, regulates activity of Cullin-RING ubiquitin ligases (CRLs) and thus indirectly co
Autor:
Kristina Xega, Michael Milhollen, Dennis Huszar, Erik Koenig, Eric S. Lightcap, Vaishali Shinde, Stephen Grossman, Keli Song, Sharon Friedlander, Omid Ghasemi, Allison Berger, Pooja Shah, Gary Shapiro, Agatha Zawadzka
Publikováno v:
Cancer Research. 79:3079-3079
TAK-981 is a small molecule inhibitor of the SUMOylation enzyme cascade which is currently in a Phase I clinical trial (NCT03648372). TAK-981 selectively inhibits the activity of the SUMO activating enzyme, forming a covalent adduct between TAK-981 a